Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Merus N.V.

A Decade of SG&A: Exelixis, Inc. vs. Merus N.V.

In the ever-evolving biotech industry, operational efficiency is key to success. Over the past decade, Exelixis, Inc. and Merus N.V. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Exelixis, Inc. has seen a staggering 967% increase in SG&A expenses from 2014 to 2023, reflecting its aggressive expansion and operational scaling. In contrast, Merus N.V.'s SG&A expenses have grown by approximately 1,454% during the same period, albeit from a much smaller base, indicating its strategic investments in growth and development.

By 2023, Exelixis, Inc.'s SG&A expenses reached nearly $543 million, while Merus N.V. reported around $60 million. This comparison highlights the differing scales and strategies of these two companies. As the biotech landscape continues to evolve, monitoring these financial metrics will be crucial for investors and stakeholders alike.